The “Rewiring” Myth? What Psilocybin Does and Doesn’t Do to Your Brain

For better or worse, the reputations of psychedelics precede them.

You’ve probably heard all sorts of claims about psilocybin.. Take the idea that psilocybin “rewires” your brain, for instance. It’s the kind of remark that gives psychedelics a certain framing, but isn’t always rooted in reality.

Despite sounding scientific, psilocybin doesn’t actually rewire the brain. At least, not in the way most people assume. Psilocybin does significantly impact the brain and, in the right circumstances, can lead to behavioral change.

Why Everyone Says Psilocybin “Rewires” the Brain

“Rewiring” is a catchy colloquialism that you don’t need a neuroscience degree to understand. But, like with most slogans, it’s an incomplete picture. Scientific researchers sparingly use “rewiring” in their publications.

A man stands on a rocky overlook watching several winding trails converge toward a lake in the valley below.

Precise language is longer, more nuanced, and less digestible to laypeople. But when it comes to understanding the potential (and limits) of psychedelics, specificity matters.

What Neuroplasticity Actually Means

When people say magic mushrooms “rewire” the brain, they’re referring to a clinically verifiable phenomenon (even if the language doesn’t line up perfectly): Neuroplasticity. Neuroplasticity broadly describes your ability to change. It’s how flexible, pliable, and receptive your brain is to new information.

There are two types of neuroplasticity. Structural plasticity refers to the physical connective tissue in your brain - think of a highway network being updated to include new merging lanes, exit ramps, or shortcuts. Functional plasticity describes how traffic flow changes as a result.

Three hikers walk separate woodland trails that curve toward the same sunlit clearing.

Psilocybin and alcohol are both considered mind-altering substances because they change your conscious perception of reality, but nobody credits booze with inducing personal breakthroughs. Psilocybin, on the other hand, has unique neuroplastic properties.

What Brain Imaging Studies Have Found

The idea that psilocybin physically rewires your brain traces back to some compelling scientific research. In 2018, Ly & colleagues published a paper claiming “psychedelics are capable of robustly increasing neuritogenesis [the formation of new neurons]…”

Other data has shown as much as +10% more neuronal connections which stuck around for at least a month after psilocybin administration.

A participant reclines in an armchair across from a clinician in a sunlit therapy room overlooking forested hills.

However, more recent research has pointed to functional connectivity (the flow of traffic) rather than paving new roads and highways. Elsewhere, in the United Kingdom, psychedelic researchers at Imperial College London have zeroed in on psilocybin’s mechanistic effects:

“The subjective effects of psychedelic drugs are caused by decreased activity in key connector hubs, enabling unconstrained cognition,” the team wrote.
More recently, functional MRI scans in a 2022 paper revealed a “rapid, sustained response” in cross-regional brain communication.

In plain English, brain imaging studies in psilocybin users reveal an acute, potent spike in brain connectivity - particularly between regions which are otherwise rigid or locked down. Psilocybin doesn’t rebuild the highway network, but it does help direct traffic and may untangle jams.

What the Research Says About Lasting Brain Changes

The evidence that psilocybin can create long-term physical or structural changes to the brain is weak (but not nonexistent). However, there’s a strong case for psilocybin having a lasting impact, especially when used as part of a larger mental health treatment plan for conditions like depression.

A woman carrying a journal walks a lakeside trail past a bench in the early morning.

More importantly, follow-up studies have shown sustained improvement for months after an acute psychedelic experience. It’s clear that psilocybin can help facilitate lasting psychological change, but perhaps not through physical “rewiring.”

Why Therapy and Integration May Matter More Than “Rewiring”

Psychedelics aren’t a triage intervention or a band-aid solution. Unlike other forms of treatment, the context before, during, and especially after ingestion can significantly impact the quality of the outcomes that result.

Psilocybin-induced neuroplasticity lasts for hours to days after the acute effects subside. Primed for change, your brain is susceptible to being molded through integration techniques like journaling, talk therapy, or somatic practice. This is why the strongest clinical research backing psychedelic therapies emphasizes doing more than just taking the drug and waiting.

Three adults sit apart in a retreat room — one journaling, one meditating on a cushion, one listening from an armchair.

Put simply, it’s very much a use-it-or-lose-it deal. Psilocybin promotes both structural and functional plasticity, but it’s not exactly clear which is responsible for the real-world changes reported by some users. Science is still trying to work out how much credit is owed to pharmacology versus real-world choices.

Frequently Asked Questions

Does psilocybin rewire your brain?

Psilocybin does not literally rewire your brain. It may promote neuroplasticity, temporarily shifting how regions in your brain communicate with one another. That said, there’s limited support to the idea that the drug creates permanent, physical change.

What is neuroplasticity?

Neuroplasticity is the brain’s ability to change in response to experiences. It includes structural reformatting and connective or networking adjustments as well. Psychedelics may acutely amplify neuroplasticity, helping users adopt new perspectives or heal deep-seated traumas.

Does psilocybin create new brain cells?

No, there’s no credible evidence that psilocybin literally creates new brain cells in humans. It may cause or assist with the formation of new neural synapses, but much of the data we have in this area comes from animal studies, not human subjects.

Sources

Kolb B, Muhammad A. Harnessing the power of neuroplasticity for intervention. Front Hum Neurosci. 2014 Jun 27;8:377. doi: 10.3389/fnhum.2014.00377. PMID: 25018713; PMCID: PMC4072970.
Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, Burbach KF, Soltanzadeh Zarandi S, Sood A, Paddy MR, Duim WC, Dennis MY, McAllister AK, Ori-McKenney KM, Gray JA, Olson DE. Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep. 2018 Jun 12;23(11):3170-3182. doi: 10.1016/j.celrep.2018.05.022. PMID: 29898390; PMCID: PMC6082376.
Shao LX, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, Kwan AC. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021 Aug 18;109(16):2535-2544.e4. doi: 10.1016/j.neuron.2021.06.008. Epub 2021 Jul 5. PMID: 34228959; PMCID: PMC8376772.
Olson DE. Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity. Biochemistry. 2022 Feb 1;61(3):127-136. doi: 10.1021/acs.biochem.1c00812. Epub 2022 Jan 21. PMID: 35060714; PMCID: PMC9004607.
Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, Tyacke RJ, Leech R, Malizia AL, Murphy K, Hobden P, Evans J, Feilding A, Wise RG, Nutt DJ. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):2138-43. doi: 10.1073/pnas.1119598109. Epub 2012 Jan 23. PMID: 22308440; PMCID: PMC3277566.
Daws RE, Timmermann C, Giribaldi B, Sexton JD, Wall MB, Erritzoe D, Roseman L, Nutt D, Carhart-Harris R. Increased global integration in the brain after psilocybin therapy for depression. Nat Med. 2022 Apr;28(4):844-851. doi: 10.1038/s41591-022-01744-z. Epub 2022 Apr 11. PMID: 35411074.
Lyons, T., Spriggs, M., Kerkelä, L. et al. Human brain changes after first psilocybin use. Nat Commun 17, 3977 (2026). https://doi.org/10.1038/s41467-026-71962-3
Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016 Jul;3(7):619-27. doi: 10.1016/S2215-0366(16)30065-7. Epub 2016 May 17. PMID: 27210031.
Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl). 2018 Feb;235(2):399-408. doi: 10.1007/s00213-017-4771-x. Epub 2017 Nov 8. PMID: 29119217; PMCID: PMC5813086.